{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[13,2,13,3],[14,2,14,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910253896203321"]
[null,null,"Titolo",null,"Biomarkers in Kidney Disease / / edited by Vinood B. Patel, Victor R. Preedy"]
[null,null,"Pubbl/distr/stampa",null,"Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2016"]
[null,null,"ISBN",null,"94-007-7699-3"]
[null,null,"Edizione",null,"[1st ed. 2016.]"]
[null,null,"Descrizione fisica",null,"1 online resource (208 illus., 150 illus. in color. eReference.)"]
[null,null,"Collana",null,"Biomarkers in Disease: Methods, Discoveries and Applications, , 2542-3657"]
[null,null,"Disciplina",null,"616.9940072"]
[null,null,"Soggetti",null,"Cancer - Research"]
[{"$nulls":4},"Oncology"]
[{"$nulls":4},"Pharmacology"]
[{"$nulls":4},"Cancer Research"]
[{"$nulls":4},"Pharmacology/Toxicology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Intro -- Volume Preface -- Series Preface -- Contents -- About the Editors -- Editorial Advisors -- Contributors -- Part I: General Aspects -- 1 Biomarkers in Kidney Transplantation -- Key Facts -- Key Facts of Operational Tolerance -- Key Facts of Costimulatory Signal -- Definitions -- Introduction -- Biomarkers of Allograft Rejection -- Urine Biomarkers -- Perforin, Granzyme B, and Fas-L mRNA -- Granzyme A mRNA -- Foxp3 mRNA -- Cytokine/Chemokine mRNA -- OX40/OX40-L mRNA -- mRNA Signature -- Urine miRNAs -- Urine Proteomics -- Blood Biomarkers -- CD30 -- Genomics -- miRNAs -- Biomarkers of -- Gene Expression Studies -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 2 Diagnostic Biomarkers of Acute Kidney Injury in Newborns -- Key Facts of Diagnostic Biomarkers of Acute Kidney Injury in Newborns -- Definitions -- Introduction -- Biomarkers of Acute Kidney Injury -- Cystatin C -- Neutrophil Gelatinase-Associated Lipocalin -- Interleukin-18 -- Kidney Injury Molecule-1 -- Fibroblast Growth Factor-2 -- Urinary Epidermal Growth Factor -- Urine Metabolomic Profiling -- Discussion -- Conclusions -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 3 Osmolal Gap as a Biomarker in Kidney Injury: Focusing on the Differential Diagnosis of Metabolic Acidosis -- Key "]
[{"$nulls":4},"Facts of the Osmolal Gap -- Definitions -- Introduction -- Definition -- Estimation of the Osmolal Gap -- Measured Osmolality -- Calculation of Osmolality -- Calculated Serum Osmolality -- Calculated Urine Osmolality -- Serum or Urine Osmolal Gap -- Clinical Utility of the Serum and Urine Osmolal Gap -- Serum Osmolal Gap -- Urine Osmolal Gap -- Limitations to the Clinical Utility of the Osmolal Gap -- Various Causes of an Osmolal Gap -- Limitations of Methods of Osmometry -- Summary Points."]
[{"$nulls":4},"References -- 4 Peritoneal Effluent Biomarker Discovery in Peritoneal Dialysis: The Omics Era -- Definitions -- Introduction -- Methodological Considerations -- Analytical Validity -- Study Designs and Population -- Omics Data Analysis -- Current Developments -- Proteomics -- Genomics and Metabolomics -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Future Directions -- Summary Points -- References -- 5 Metabolomics and Stages of Chronic Kidney Disease -- Key Facts About Metabolomics and Stages of Chronic Kidney Disease -- Definitions -- Introduction -- Why Use Metabolomics to Diagnose CKD -- Using Mass Spectrometry for Metabolite Exploration -- Nontarget Analysis and Target Analysis -- Nontarget Analysis -- Target Analysis (Multi-target Analysis) -- Future of Metabolomics in the Diagnosis of Disease -- Potential Applications to Prognosis and Other Diseases and Conditions -- Summary Points -- References -- 6 Hypoxia as a Biomarker of Kidney Disease -- Key Facts of Kidney Oxygenation -- Definitions -- Introduction -- Chronic Kidney Disease -- The Role of Hypoxia in the Pathogenesis of Chronic Kidney Disease -- The Clinical Problem: Early Diagnosis and Instigation of Therapy -- Assessment of Kidney Oxygenation by BOLD MRI in Chronic Kidney Disease -- Acute Kidney Injury -- The Role of Hypoxia in the Pathogenesis of Acute Kidney Injury -- The Clinical Problem: Prevention of Acute Kidney Injury in the Hospital Setting -- Cardiac Surgery -- Sepsis -- Radiocontrast Agents and Other Nephrotoxins -- Urinary PO2 as a Diagnostic Biomarker in Acute Kidney Injury -- Potential Applications to Prognosis, Other Disease and Conditions -- Summary Points -- References -- 7 MicroRNAs in Kidney Diseases -- Key Facts -- Key Facts of Renal Physiology -- Key Facts of PKD -- Key Facts of Primary and Secondary Glomerulonephritis."]
[{"$nulls":4},"Key Facts of Kidney Transplantation -- Key Facts of miRNA Therapy -- Definitions -- Introduction: Biogenesis of miRNAs -- New Strategies for Detection of Renal miRNA -- MiRNAs in Renal Physiology -- Blood Flow and Oxygen Supply -- Glomerular Filtration -- Tubular Reabsorption and Excretion -- Interstitial Osmolarity -- MiRNAs in Polycystic Kidney Disease -- MiRNAs in Primary and Secondary Glomerulonephritis -- MiRNAs in Kidney Transplantation -- Potential Applications to Prognosis and Other Diseases or Conditions -- MiRNAs as Diagnostic Tools in Blood and Urine -- New Approaches for miRNA Therapy -- Therapeutic Approaches -- MiRNAs as Potential Therapeutic Strategies -- Challenges and Future Perspectives -- Summary Points -- References -- 8 Serum Creatinine Trajectories in Kidney Disease -- Key Facts -- Definitions -- Introduction -- Creatinine: Metabolism, Chemical Structure, and Excretion in the Urine -- Serum Creatinine Trajectories in Kidney Disease -- Serum Creatinine Trajectories in Acute Kidney Injury (AKI): The Rainbow Spectrum of Renal Outcomes Following AKI in CKD Patien... -- Rapid and Full Recovery of Renal Function Following AKI on CKD -- Partial Recovery of Renal Function Following AKI on CKD -- Rapid-Onset Yet Irreversible ESRD or the Syndrome of Rapid-Onset ESRD (SORO-ESRD) Following AKI on CKD in a Patient with Nativ... -- Rapid-Onset Yet Irreversible ESRD or the Syndrome of Rapid-Onset ESRD (SORO-ESRD) Following AKI on CKD in "]
[{"$nulls":4},"a Renal Transplant R... -- Serum Creatinine Trajectories in Adult Polycystic Kidney Disease (ADPKD): An Nnamdi Azikiwe University Teaching Hospital, New... -- Case I -- Case II -- Serum Creatinine Trajectories in Chronic Kidney Disease: The NKF KDOQI CKD Staging Paradigm Revisited: CKD Prediction Is an In... -- Stable CKD V Over 7Years in a Now 78-Year-Old Caucasian Hypertensive Diabetic Male."]
[{"$nulls":4},"Stable CKD IV Over 8Years in a Now 78-Year-Old Caucasian Hypertensive Diabetic Male -- Stable CKD III Over Nearly 10Years in a Now 87-Year-Old Caucasian Hypertensive Male -- Two Divergent Patterns of CKD to ESRD Progression: The ``Classic´´ Pattern and the Pattern of the Syndrome of Rapid-Onset End-... -- ``Classic´´ Pattern of CKD-ESRD Progression in a Hypertensive Caucasian Male -- ``Classic´´ Pattern of CKD-ESRD Progression in a Caucasian Hypertensive Diabetic Male -- Pattern of Syndrome of Rapid-Onset ESRD in a Caucasian Hypertensive Diabetic Male -- Late-Onset End-Stage Renal Failure from Angiotensin Blockade (LORFFAB) -- Serum Creatinine Trajectories in a Case of ``Quadruple Whammy´´ -- Perioperative AKI and Concurrent Angiotensin Inhibition Alone: A Case Presentation from Mayo Clinic Health System, Eau Claire,... -- Serum Creatinine Trajectories in HIV-Associated Nephropathy: An Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, R... -- Case I -- Case II -- Serum Creatinine Trajectories in Sickle Cell Disease Nephropathy: An Nnamdi Azikiwe University Teaching Hospital, Nnewi, Niger... -- Conclusions: A Need for More Preventative Renal Medicine: Renoprevention Revisited. The Introduction of the New Innovative CKD... -- Potential Applications of Serum Creatinine Trajectories in Kidney Disease Prognostication and Management -- Summary Points -- References -- 9 Random Spot Urine Markers for Kidney and Their Applications -- Key Facts of Urinalysis -- Definitions -- Introduction -- The Specimen for Analysis -- Physical Markers -- Color -- Odor -- Turbidity or Clarity -- Relative Density -- Chemical Markers -- Blood -- pH -- Bilirubin -- Urobilinogen -- Ketones -- Nitrites and Leukocyte Esterase -- Glucose -- Albuminuria -- Protein -- Uric Acid -- Electrolytes -- Sodium -- Potassium -- Phosphate -- Others -- Microscopic Markers."]
[{"$nulls":4},"Erythrocytes -- Leukocytes -- Cells -- Lipids -- Casts -- Crystals -- Organisms -- Conclusions -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 10 Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology -- Key Facts of Creatinine -- Definitions -- Introduction -- NGAL and Acute Kidney Injury -- NGAL and Autosomal-Dominant Polycystic Kidney Disease (ADPKD) -- NGAL and Chronic Kidney Disease -- NGAL in Kidney Transplant Patients -- Potential Applications to Prognosis and Other Diseases or Conditions -- Summary Points -- References -- 11 Chemokines as Potential Markers in Pediatric Renal Diseases -- Key Facts of Chemokines in Pediatric Renal Disease -- Definitions -- Chemokines: General Concepts -- Chemokines in Renal Diseases -- Chemokines in Glomerular Diseases -- Chemokines in Congenital Uropathies -- Ureteropelvic Junction Obstruction -- Vesicoureteral Reflux -- Potential Applications to Prognosis, Other Diseases or Conditions -- Summary Points -- References -- 12 Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers -- Key Facts of Renal Disease Subsequent to Neoplasia -- Key Facts of Neoplasia Risk in Renal Patients -- Key Facts of Neoplasia Risk in Renal Patients -- Definitions -- Introduction -- Renal Disease Associated with Malignancies -- Malignancy Associated with Renal Disease -- Breast Cancer -- Colorectal Cancer -- Women-Specific Tumoral Diseases: "]
[{"$nulls":4},"Cervical Cancer and Ovary Cancer -- Lung Cancer -- Liver Cancer -- Prostate Cancer -- Tumors of the Urinary Tract: Kidney, Ureters, and Bladder -- Markers of Cancer and Renal Function -- Conclusions -- Summary Points -- References -- Part II: Circulating and Body Fluid Biomarkers -- 13 Creatinine Assays in Early Infancy: How to Aim for a Moving Target."]
[{"$nulls":4},"Key Facts of Creatinine Assays and Their Clinical Relevance in Early Infancy."]
[null,null,null,"Sommario/riassunto","In some countries such as the United States, kidney disease kills more people than cancers of the prostate or breast. In the United States for example there are over 15 million individuals with kidney disease. Translated to a worldwide basis, kidney disease of various aetiologies represent a significant burden on healthcare systems, affecting mortality, morbidity and also the family unit. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms to aid diagnosis, treatment and an understanding of outcome measures.  Biomarkers in Kidney Disease embraces a holistic approach by combining information on different conditions that affect the kidney and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge and trends. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.  ."]